AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease and Neuroscience Pipeline
AbbVie (NYSE: ABBV) has announced the acquisition of Aliada Therapeutics for $1.4 billion in cash, strengthening its neuroscience pipeline. The deal centers on Aliada's lead compound ALIA-1758, an anti-pyroglutamate amyloid beta antibody in development for Alzheimer's disease, currently in Phase 1 trials. The acquisition includes Aliada's proprietary MODEL™ platform, featuring novel blood-brain barrier crossing technology that targets transferrin and CD98 receptors for enhanced CNS drug delivery. The transaction is expected to close in Q4 2024, subject to regulatory approvals.
AbbVie (NYSE: ABBV) ha annunciato l'acquisizione di Aliada Therapeutics per 1,4 miliardi di dollari in contante, rafforzando la sua pipeline di neuroscienze. L'accordo si concentra sul composto principale di Aliada, ALIA-1758, un anticorpo anti-piroglutammato dell'amiloide beta in fase di sviluppo per la malattia di Alzheimer, attualmente in fase 1 di sperimentazione. L'acquisizione include la piattaforma proprietaria di Aliada, MODEL™, che presenta una tecnologia innovativa per attraversare la barriera emato-encefalica, mirata ai recettori transferrina e CD98 per un potenziamento della somministrazione di farmaci nel sistema nervoso centrale. Si prevede che la transazione si concluda nel quarto trimestre del 2024, soggetta ad approvazioni normative.
AbbVie (NYSE: ABBV) ha anunciado la adquisición de Aliada Therapeutics por 1,4 mil millones de dólares en efectivo, fortaleciendo su cartera de neurociencia. El acuerdo se centra en el compuesto principal de Aliada, ALIA-1758, un anticuerpo anti-piroglutamato de amiloide beta en desarrollo para la enfermedad de Alzheimer, actualmente en ensayos de Fase 1. La adquisición incluye la plataforma propietaria de Aliada, MODEL™, que cuenta con una tecnología novedosa para cruzar la barrera hematoencefálica, que se dirige a los receptores de transferrina y CD98 para una mejor entrega de medicamentos en el sistema nervioso central. Se espera que la transacción se cierre en el cuarto trimestre de 2024, sujeto a aprobaciones regulatorias.
AbbVie (NYSE: ABBV)는 Aliada Therapeutics를 현금으로 14억 달러에 인수했다고 발표하며, 신경과학 파이프라인을 강화하고 있습니다. 이 거래는 알츠하이머병 치료를 위해 개발 중인 피루글루타메이트 아밀로이드 베타 항체인 Aliada의 주요 화합물 ALIA-1758에 초점을 맞추고 있으며 현재 1상 시험 중입니다. 인수에는 혈액-뇌 장벽을 통과하는 혁신적인 기술을 자랑하는 Aliada의 독점 MODEL™ 플랫폼이 포함되어 있으며, 이는 CNS 약물 전달을 향상시키기 위해 트랜스페린 및 CD98 수용체를 표적합니다. 이 거래는 규제 승인에 따라 2024년 4분기에 마무리될 것으로 예상됩니다.
AbbVie (NYSE: ABBV) a annoncé l'acquisition de Aliada Therapeutics pour 1,4 milliard de dollars en espèces, renforçant ainsi son pipeline en neurosciences. L'accord se concentre sur le composé principal d'Aliada, ALIA-1758, un anticorps anti-pyroglutamate beta-amyloïde en développement pour la maladie d'Alzheimer, actuellement en phase 1 des essais. L'acquisition comprend la plateforme propriétaire d'Aliada, MODEL™, qui présente une nouvelle technologie de passage de la barrière hémato-encéphalique, ciblant les récepteurs de transferrine et CD98 pour améliorer la délivrance de médicaments au système nerveux central. La transaction devrait se conclure au quatrième trimestre 2024, sous réserve des approbations réglementaires.
AbbVie (NYSE: ABBV) hat die Übernahme von Aliada Therapeutics für 1,4 Milliarden Dollar in bar angekündigt, um seine Neurowissenschafts-Pipeline zu stärken. Der Deal konzentriert sich auf die Hauptverbindung von Aliada, ALIA-1758, einen Anti-Pyroglutamat-Amyloid-Beta-Antikörper, der für die Behandlung von Alzheimer entwickelt wird und sich derzeit in Phase-1-Studien befindet. Die Übernahme umfasst auch Aliadas proprietäre MODEL™-Plattform, die eine neuartige Technologie zur Überwindung der Blut-Hirn-Schranke bietet und auf Transferrin- und CD98-Rezeptoren abzielt, um die Medikamentenverabreichung im zentralen Nervensystem zu verbessern. Der Abschluss der Transaktion wird im vierten Quartal 2024 erwartet, vorbehaltlich der behördlichen Genehmigungen.
- Acquisition of promising Alzheimer's disease therapy ALIA-1758 in clinical development
- Access to innovative blood-brain barrier crossing technology platform (MODEL™)
- Strategic expansion in neuroscience, a key growth area
- Technology could accelerate development of multiple CNS therapies
- Significant cash outlay of $1.4 billion for early-stage asset
- ALIA-1758 still in early Phase 1 trials with uncertain outcomes
- Regulatory approval pending for transaction completion
Insights
This
While the acquisition price appears substantial for a Phase 1 asset, the BBB-crossing platform technology provides significant long-term value potential across multiple therapeutic areas. This move aligns with AbbVie's strategy to diversify beyond Humira and strengthen its position in neuroscience, a high-growth therapeutic area with substantial unmet needs.
The MODEL™ platform's dual-receptor targeting approach (TfR and CD98) represents a significant technological advancement in CNS drug delivery. Current Alzheimer's treatments face efficacy limitations due to poor brain penetration, making this technology particularly valuable. ALIA-1758's focus on pyroglutamate amyloid beta (3pE-Aβ) offers a potentially more precise approach compared to existing anti-amyloid therapies.
The platform's versatility in delivering both antibodies and genetic medicines could be revolutionary for treating various neurological conditions. While still in early clinical stages, the technology's ability to enhance brain penetration could lead to lower dosing requirements and potentially better safety profiles for CNS therapeutics.
- Aliada's lead compound, ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, is a potential best-in-class therapy for Alzheimer's disease
- Acquisition also allows AbbVie to utilize Aliada's novel blood-brain barrier (BBB)-crossing technology to enhance discovery and development efforts across neuroscience
"Neuroscience is one of our key growth areas and we are committed to driving innovation in this field to address critical unmet needs for patients living with seriously debilitating neurological diseases such as Alzheimer's disease," said Roopal Thakkar, M.D., executive vice president, research and development and chief scientific officer, AbbVie. "This acquisition immediately positions us to advance ALIA-1758, a potentially best-in-class disease-modifying therapy for Alzheimer's disease. In addition, Aliada's novel BBB-crossing technology strengthens our R&D capabilities to accelerate the development of next-generation therapies for neurological disorders and other diseases where enhanced delivery of therapeutics into the CNS is beneficial."
"We are pleased to announce the acquisition of Aliada by AbbVie and are excited about AbbVie's commitment to bringing ALIA-1758 to patients with Alzheimer's disease. Our proprietary MODEL™ platform has enabled the development of ALIA-1758, a promising step forward in brain delivery of an anti-amyloid antibody therapy," said Michael Ryan, M.D., chief medical officer at Aliada Therapeutics. "Many promising CNS-targeted therapies fail to reach late-stage trials due to their inability to cross the blood-brain barrier. Our MODEL™ platform addresses this challenge directly, efficiently delivering targeted drugs and potentially transforming how we treat neurological diseases."
Aliada is advancing therapeutic candidates using its Modular Delivery (MODEL™) platform, engineered for high-precision CNS drug delivery. The novel BBB-crossing technology targets transferrin and CD98 receptors (TfR and CD98) which are highly expressed in brain endothelial cells. By engineering highly optimized TfR or CD98 binders, this platform is designed to deliver different types of biological cargoes into the brain, including therapeutic antibodies and genetic medicines such as siRNA.
ALIA-1758 utilizes TfR to transport a 3pE-Aβ antibody across the BBB to enable degradation and elimination of amyloid beta plaques, a pathological hallmark of Alzheimer's disease. This investigational candidate is currently in a Phase 1 clinical trial to assess its safety and tolerability in healthy participants (NCT06406348).
Under the terms of the agreement, AbbVie will acquire all outstanding Aliada equity for
Advisors
AbbVie's legal advisor was Covington & Burling LLP. Aliada's exclusive financial advisor was Centerview Partners LLC and Fenwick & West LLP served as legal advisor.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.
About Aliada Therapeutics
Aliada Therapeutics is a biotechnology company focused on addressing delivery challenges in CNS drug development. Aliada is developing next-generation CNS therapeutics with its novel BBB-crossing Modular Delivery (MODEL™) platform technology, which has been shown to efficiently transport diverse therapeutic cargoes into the brain, enhancing effectiveness and addressing the critical need for efficient and versatile large molecule and oligonucleotide delivery. Johnson & Johnson (through its venture capital arm, Johnson & Johnson Innovation – JJDC, Inc.), RA Capital Management, and Raven (RA Capital Management's incubator) co-founded Aliada and co-led the series seed financing in 2021 to advance the MODEL™ platform created by Johnson & Johnson scientists that was licensed to Aliada at its inception. Further investment was made by OrbiMed and Sanofi Ventures.
For more information visit www.aliadatx.com and follow us on LinkedIn and X.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/abbvie-to-acquire-aliada-therapeutics-strengthening-focus-in-alzheimers-disease-and-neuroscience-pipeline-302288180.html
SOURCE AbbVie
FAQ
How much is AbbVie (ABBV) paying to acquire Aliada Therapeutics?
What is the main asset AbbVie (ABBV) is acquiring from Aliada Therapeutics?
When is the AbbVie (ABBV) acquisition of Aliada expected to close?
What technology will AbbVie (ABBV) gain through the Aliada acquisition?
